Evaluation of the effect of cannabidiol in the treatment of schizophrenic patients
Phase 3
- Conditions
- Schizophrenia.Schizophrenia
- Registration Number
- IRCT20210310050660N2
- Lead Sponsor
- Qazvin University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
All patients with schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders (DSM–5) criteria
Hospitalized in 22 Bahman Hospital in Qazvin
Candidate for treatment only with rispidone as an antipsychotic
Patient and legal guardian willingness to enter the study
Positive and Negative Syndrome Scale (PANSS) score over 60 When entering the study
Absence of cognitive disorders
Lack of drug resistance
Exclusion Criteria
Breastfeeding and pregnancy or desire to conceive within 3 months after completion of the plan.
Consumption of stimulants and hallucinogens and cannabis
Patients with schizophrenia without positive symptoms
candidate for Electroconvulsive Therapy (ECT)
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Positive symptoms. Timepoint: At the beginning of the study (before the intervention) and 2, 4 and 6 weeks after the start of treatment. Method of measurement: PANSS Questionnaire Scores (Anderson Test).
- Secondary Outcome Measures
Name Time Method